分子伙伴预计将在2025年开始其DLL3目标癌症治疗MP0712的第一阶段试验。 Molecular Partners expects to begin Phase 1 trials for its DLL3-targeting cancer therapy MP0712 in 2025.

分子伙伴宣布其2025年Q3财政结果和最新临床进展,指出其DLL3定向DARL3无线电-DARPin疗法的第一阶段试验(MP0712)预计将在2025年开始。 Molecular Partners announced its Q3 2025 financial results and updated clinical progress, stating that the Phase 1 trial for its DLL3-targeting radio-DARPin therapy, MP0712, is expected to begin in 2025. 该公司报告正在开发其输油管,MP0712正在推进临床评价,以治疗显示DLL3蛋白质的癌症。 The company reported ongoing development of its pipeline, with MP0712 advancing toward clinical evaluation for treating cancers expressing the DLL3 protein. 目前没有提供关于试验设计或患者入学的进一步详情。 No further details on trial design or patient enrollment were provided at this time.